Company Ticker News December 2, 2021Merck, Novartis in Line for Key FDA Approvals This Month 0 0 Share
Press Release December 1, 2021U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Merck's VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for Use in Infants and Children 0 0 Share
Press Release December 1, 2021Merck's Pneumococcal 15-valent Conjugate Vaccine Under Priority FDA Review For Use In Kids 0 0 Share
Company Ticker News December 1, 2021After high hopes for Merck's COVID-19 pill, Wall Street now expects a ‘tepid' authorization 0 0 Share
Company Ticker News November 30, 2021Is Merck stock a buy or sell as covid pill efficacy concerns send shares crushing? 0 0 Share
Company Ticker News November 30, 2021FDA Panel Recommends Merck's Covid-19 Antiviral Pill For Emergency Use Authorization 0 0 Share
Company Ticker News November 30, 2021FDA advisory panel narrowly endorses Merck's oral Covid treatment pill, despite reduced efficacy and safety questions 0 0 Share
Company Ticker News November 30, 2021An FDA expert panel narrowly supports the first COVID-19 pill but suggests restrictions on its use driven by safety concerns 0 0 Share
Press Release November 30, 2021Merck and Ridgeback Statement on Positive FDA Advisory Committee Vote for Investigational Oral Antiviral Molnupiravir for Treatment of Mild to Moderate COVID-19 in High Risk Adults 0 0 Share
Company Ticker News November 30, 2021FDA panel narrowly moves to authorize Merck's COVID treatment pill 0 0 Share
